{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:40:03Z","timestamp":1759210803236,"version":"3.44.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl. Int."],"abstract":"<jats:p>Lymphocyte depleting induction is recommended for kidney transplant recipients (KTRs) at high immunological risk, which traditionally includes those with detectable anti-human leucocyte antigen antibodies. Data to support this approach in the modern era of histocompatibility testing are limited. We investigated outcomes in KTRs who underwent Basiliximab induction between 2012\u20132023 in the UK. We stratified outcomes by levels of sensitisation and T cell epitope mismatch (PIRCHE-II) scores. 1348 KTRs were included; 859 (63.7%) were unsensitised, 351 (26.0%) sensitised (calculated reaction frequency [cRF] 1%\u201384%), and 138 (10.3%) highly sensitised (cRF 85%\u2013100%). Patient survival, allograft survival, and death-censored graft survival (DCGS) were 97%, 94%, and 97% at 1 year, and 88%, 78%, and 84% at 5\u00a0years respectively. There were no differences in outcomes between unsensitised and sensitised recipients; graft survival was lower in highly sensitised patients. T cell epitope mismatch scores were higher in those with rejection at 1 year (ln[PIRCHE+1] 3.94 \u00b1 1.01 no rejection vs. 4.25 \u00b1 0.58 rejection, p = 0.02) and epitope mismatch was associated with early rejection in multivariable analyses (Odds Ratio 1.58, 95% CI 1.01\u20132.62). Hence, non-depleting induction provides good outcomes in unsensitised and sensitised KTRs. T cell epitope mismatches inform rejection risk in the first post-transplant year.<\/jats:p>","DOI":"10.3389\/ti.2025.14852","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:10:25Z","timestamp":1759209025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Kidney Transplant Outcomes With Non-Depleting Antibody Induction Therapy in Human Leucocyte Antigen Sensitised Recipients"],"prefix":"10.3389","volume":"38","author":[{"given":"Ria","family":"Nagpal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Thal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Hobill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Gage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Karst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azhar Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Needleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Shirling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Vivers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Tavarozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neema","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Frater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Harber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhys D. R.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive Drugs for Kidney Transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"CD003897","DOI":"10.1002\/14651858.CD003897.pub3","article-title":"Interleukin 2 Receptor Antagonists for Kidney Transplant Recipients","volume":"2010","author":"Webster","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/tri.13079","article-title":"Center Practice Drives Variation in Choice of US Kidney Transplant Induction Therapy: A Retrospective Analysis of Contemporary Practice","volume":"31","author":"Dharnidharka","year":"2018","journal-title":"Transpl Int Off J Eur Soc Organ Transpl"},{"key":"B4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/ajt.13884","article-title":"Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies?","volume":"17","author":"Hellemans","year":"2017","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1111\/ajt.13930","article-title":"Yes, We Still Need IL-2 Receptor Antagonists","volume":"16","author":"Fleming","year":"2016","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients","volume":"9","year":"2009","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"c311","DOI":"10.1159\/000328074","article-title":"Renal Association Clinical Practice Guideline on Post-operative Care of the Kidney Transplant Recipient","volume":"118","author":"Baker","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1046\/j.1600-6135.2003.00273.x","article-title":"Pre-Transplant Assessment of Donor-Reactive, HLA-Specific Antibodies in Renal Transplantation: Contraindication vs. Risk","volume":"3","author":"Gebel","year":"2003","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00007890-200301150-00008","article-title":"Single Human Leukocyte Antigen Flow Cytometry Beads for Accurate Identification of Human Leukocyte Antigen Antibody Specificities","volume":"75","author":"Pei","year":"2003","journal-title":"Transplantation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-6143.2009.02927.x","article-title":"Calculated PRA (CPRA): The New Measure of Sensitization for Transplant Candidates","volume":"10","author":"Cecka","year":"2010","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"10511","DOI":"10.3389\/ti.2022.10511","article-title":"European Guideline for the Management of Kidney Transplant Patients with HLA Antibodies: By the European Society for Organ Transplantation Working Group","volume":"35","author":"Mamode","year":"2022","journal-title":"Transpl Int Off J Eur Soc Organ Transpl"},{"key":"B12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.humimm.2006.10.003","article-title":"HLAMatchmaker: A Molecularly Based Algorithm for Histocompatibility Determination. V. Eplet Matching for HLA-DR, HLA-DQ, and HLA-DP","volume":"68","author":"Duquesnoy","year":"2007","journal-title":"Hum Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00251-019-01140-x","article-title":"PIRCHE-II: An Algorithm to Predict Indirectly Recognizable HLA Epitopes in Solid Organ Transplantation","volume":"72","author":"Geneugelijk","year":"2020","journal-title":"Immunogenetics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients","volume":"20","author":"No\u00ebl","year":"2009","journal-title":"J Am Soc Nephrol JASN"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"B17","unstructured":"BTS-NHSBT-2025-Abstract-Book-Final-3.pdf"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1111\/ajt.17175","article-title":"ABO-Adjusted Calculated Panel Reactive Antibody (cPRA): A Unified Metric for Immunologic Compatibility in Kidney Transplantation","volume":"22","author":"Gragert","year":"2022","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1053\/j.ajkd.2022.06.005","article-title":"Molecular Mismatch and the Risk for T Cell-Mediated Rejection","volume":"80","author":"Wiebe","year":"2022","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"B20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fimmu.2018.00321","article-title":"PIRCHE-II Is Related to Graft Failure after Kidney Transplantation","volume":"9","author":"Geneugelijk","year":"2018","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/lt.26431","article-title":"Assessment of Human Leukocyte Antigen Matching Algorithm PIRCHE\u2010II on Liver Transplantation Outcomes","volume":"28","author":"Kok","year":"2022","journal-title":"Liver Transpl"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ajt.2025.01.020","article-title":"OPTN\/SRTR 2023 Annual Data Report: Kidney","volume":"25","author":"Lentine","year":"2025","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B23","unstructured":"ODT Clinical - NHS Blood and Transplant"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1056\/NEJMc0805714","article-title":"Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction","volume":"359","author":"Brennan","year":"2008","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/ajt.13191","article-title":"Daclizumab versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-Up of a Randomized Study","volume":"15","author":"Hellemans","year":"2015","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s13063-015-0891-y","article-title":"Long-Term Safety and Efficacy of Antithymocyte Globulin Induction: Use of Integrated National Registry Data to Achieve Ten-Year Follow-Up of 10-10 Study Participants","volume":"16","author":"Kl","year":"2015","journal-title":"Trials"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/S0140-6736(16)32187-0","article-title":"Rabbit-ATG or Basiliximab Induction for Rapid Steroid Withdrawal after Renal Transplantation (Harmony): An Open-Label, Multicentre, Randomised Controlled Trial","volume":"388","author":"Thomusch","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"B28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/ndt\/gfad130","article-title":"Excellent Efficacy and Beneficial Safety during Observational 5-Year Follow-Up of Rapid Steroid Withdrawal after Renal Transplantation (Harmony FU Study)","volume":"39","author":"Stumpf","year":"2023","journal-title":"Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.ekir.2020.05.020","article-title":"A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients","volume":"5","author":"Kamar","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/SLA.0b013e318187d1da","article-title":"A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation versus Long-Term, Low-Dose Corticosteroid Therapy","volume":"248","author":"Woodle","year":"2008","journal-title":"Ann Surg"},{"key":"B31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamasurg.2020.6929","article-title":"Early Corticosteroid Cessation vs Long-Term Corticosteroid Therapy in Kidney Transplant Recipients: Long-Term Outcomes of a Randomized Clinical Trial","volume":"156","author":"Woodle","year":"2021","journal-title":"JAMA Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/SLA.0000000000000496","article-title":"Prospective Randomized Controlled Trial of Rabbit Antithymocyte Globulin Compared with IL-2 Receptor Antagonist Induction Therapy in Kidney Transplantation","volume":"259","author":"Pilch","year":"2014","journal-title":"Ann Surg"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab Induction in Renal Transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2215\/CJN.08710814","article-title":"Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate with or without Steroid Maintenance","volume":"10","author":"Tanriover","year":"2015","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2215\/CJN.13171215","article-title":"Acute Rejection Rates and Graft Outcomes According to Induction Regimen Among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate","volume":"11","author":"Tanriover","year":"2016","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B36","doi-asserted-by":"publisher","first-page":"10138","DOI":"10.3389\/ti.2022.10138","article-title":"Alloimmune Risk Stratification for Kidney Transplant Rejection","volume":"35","author":"Bestard","year":"2022","journal-title":"Transpl Int"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1111\/ajt.14247","article-title":"Donor Specificity but Not Broadness of Sensitization Is Associated with Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients","volume":"17","author":"Wehmeier","year":"2017","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B38","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/tri.13428","article-title":"Increased Risk of Rejection after Basiliximab Induction in Sensitized Kidney Transplant Recipients without Pre-Existing Donor-specific Antibodies - A Retrospective Study","volume":"32","author":"Goumard","year":"2019","journal-title":"Transpl Int Off J Eur Soc Organ Transpl"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1111\/ajt.14393","article-title":"Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation","volume":"17","author":"Lachmann","year":"2017","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.trim.2018.06.006","article-title":"The Clinical Significance of Epitope Mismatch Load in Kidney Transplantation: A Multicentre Study","volume":"50","author":"Dani\u00ebls","year":"2018","journal-title":"Transpl Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"631246","DOI":"10.3389\/fimmu.2021.631246","article-title":"Can PIRCHE-II Matching Outmatch Traditional HLA Matching?","volume":"12","author":"Unterrainer","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"949933","DOI":"10.3389\/fimmu.2022.949933","article-title":"PIRCHE-II Scores Prove Useful as a Predictive Biomarker Among Kidney Transplant Recipients with Rejection: An Analysis of Indication and Follow-Up Biopsies","volume":"13","author":"Spitznagel","year":"2022","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"788818","DOI":"10.3389\/fimmu.2022.788818","article-title":"High PIRCHE Scores May Allow Risk Stratification of Borderline Rejection in Kidney Transplant Recipients","volume":"13","author":"Lezoeva","year":"2022","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1600-6143.2006.01677.x","article-title":"Protocol Biopsies in Renal Transplantation: Insights into Patient Management and Pathogenesis","volume":"7","author":"Mengel","year":"2007","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B45","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/TP.0000000000000031","article-title":"Antithymocyte Globulin Is Associated with a Lower Incidence of De Novo Donor-Specific Antibodies in Moderately Sensitized Renal Transplant Recipients","volume":"97","author":"Brokhof","year":"2014","journal-title":"Transplantation"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2025.14852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:10:27Z","timestamp":1759209027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2025.14852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":45,"alternative-id":["10.3389\/ti.2025.14852"],"URL":"https:\/\/doi.org\/10.3389\/ti.2025.14852","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"14852"}}